Sign inJoin waitlistJoin the waitlist

Scott Moerdler

Program Director, Pediatric Hematology/Oncology Fellowship · Rutgers Health

Credentials: · ·

History

Pediatric Hematology/Oncology Fellowship · Rutgers Health
Present
Rutgers Health
Present
Rutgers Health
Present

Pediatric Hematology Oncology
Montefiore Medical Center/Albert Einstein College of Medicine
2015–2018
Kravis Children’s Hospital
2012–2015
Icahn School of Medicine at Mount Sinai
2008–2012
Brandeis University

Research

KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target
Science Immunology · 2021 · 73 citations
New insights into the pathophysiology and development of novel therapies for sickle cell disease
Review · Hematology. American Society of Hematology. Education Program · 2018 · First of 2 authors · 28 citations
Physician perspectives on compassionate use in pediatric oncology
Pediatric Blood & Cancer · 2019 · First of 8 authors · 22 citations

Jennifer Kesselheim
6 papers
Michael Roth
6 papers
Suzanne Friedman
5 papers
Adit Tal
4 papers
AC
Alexander Chou
4 papers
Daniel Weiser
4 papers
Jennifer Levine
4 papers
JP
Joanna Pierro
4 papers
Prakash Satwani
4 papers
Scott Borinstein
4 papers
AO
Andrea Orsey
3 papers
Anshul Vagrecha
3 papers

Clinical trials

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2029
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Site PI · Recruiting · Phase 3
Children's Oncology Group
2022–2030